Current Research Studies

Evaluates the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)  Mark Bieniarz, P.I.; Jo Pressler, CCRC

Evaluates the usage of advanced features and diagnostics in SJM pacemakers.  Sean Mazer, P.I.; Judi Everett, RN; Marlene Kravtiz, CCRC

This is a registry utilizing an already FDA approved stent (Carotid WALLSTENT Monorail Endoprosthesis and FilterWire EZ Embolic Protection System).  Additional information is being collected about the stent and embolic protection system, details of the stenting procedure as well as information about patients treated with the stent.  Steve Henao, P.I.; Paul Brennan, RN

Evaluates the outcome of patients with Atrial Fibrillation requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure.  The trial population includes patients requiring valve replacemnts or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.  Paul Levy, P.I.; Marlene Kravitz, CCRC

Evaluation of efficacy and safety of EDOXABAN (Effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation) vs. Warfarin in subjects with Atrial Fibrillation.  CHADS score of 3 - 6 required; patients must be able to attend anticoagulation visits at NMHI).  Robert C. Orchard, P.I.; LuAnna Garcia, CRC

Compares benefit and safety of Vytorin vs. Simvastatin in Hi-Risk patients presenting with Acute Coronary Syndrome (ACS).  Robert C. Orchard, P.I.; Marlene Kravitz, CCRC.

Compares the On-X valve on low dose anticoagulation to concomitant groups of On-X valves receiving standard coumadin/aspirin therapy and to also drive FDA objective performance criteria (OPC).  Paul Levy, P.I.; Marlene Kravitz, CCRC.

This study will compare the capability of an already FDA approved CRT device (cardiac resynchronization therapy device) by either allowing the device to self-optimize its settings or the device will be manually programmed by the implanting doctor to optimize the settings.  Sean Mazer, P.I.; Marlene Kravtiz, CCRC

This study follows the programming of Implantable Cardioverter Defibrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock.  Sean Mazer, P.I.; Marlene Kravitz, CCRC

Determine whether periodoc therapy programming reports illustrate if physician usage of shock reduction programming can increase utiliztion of recommended programming guideliens for defibrillators.  Sean Mazer, P.I.; Marlene Kravitz, CCRC.

Post approval study of a Paclitaxel-Eluting Coronary Stent System.  Robert E. Federici, P.I.; Marlene Kravitz, CCRC.

DEFINITIVE LE - Determiniation of Effectiveness of the SilverHawk Peripheral Plaque Excision System (SilverHawk Device) for the Teatment of Infrainguinal Vessels/Lower Extremities.  Steve Henao, P.I.; Paula Brennan, RN.

PARADIGM - HF - Evaluates the Effectiveness and Safety of a Newly Devised Drug in Patients with Chronic Heart Failure.  Robert C. Orchard, P.I.

TAO - Comparing the Efficacy of otamixaban with Unfractionated heparin + eptifibatide, in patients with Unstable angina/Non ST  segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy.  Mark Bieniarz, P.I.